Review Article | Published:

Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau

Nature Neuroscience volume 1, pages 355358 (1998) | Download Citation

Subjects

  • A Correction to this article was published on 01 December 1998

Abstract

Molecular genetic analysis is revealing the etiologies of Alzheimer's disease (AD) and related dementias. Here we review genetic and molecular biological evidence suggesting that the peptide Aβ42 is central to the etiology of AD. Recent data also suggests that dysfunction in the cytoskeletal protein tau is on the pathway that leads to neurodegeneration and dementia. Tau is produced either indirectly, by Aβ42, or directly, in some forms of frontotemporal dementia by mutations in tau itself. These data support and refine the amyloid cascade hypothesis for AD and suggest that understanding the causes and consquences of tau dysfunction is an important priority for dementia research.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383–388 ( 1991).

  2. 2.

    Amyloid β-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271, 18295–18298 (1996).

  3. 3.

    Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154–159 (1997).

  4. 4.

    et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704–706 (1991).

  5. 5.

    et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754– 760 (1995).

  6. 6.

    et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973–977 ( 1995).

  7. 7.

    et al. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693– 4697 (1993).

  8. 8.

    et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672–674 (1992).

  9. 9.

    et al. Release of excess amyloid β-protein from a mutant amyloid β-protein precursor. Science 259, 514– 516 (1993).

  10. 10.

    et al. An increased percentage of long amyloid β-protein secreted by familial amyloid β-protein precursor (β-APP717) mutants. Science 264, 1336–1340 ( 1994).

  11. 11.

    et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864–870 (1996).

  12. 12.

    et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710–713 (1996).

  13. 13.

    et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005 –1013 (1996).

  14. 14.

    et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med. 3, 67–72 ( 1997).

  15. 15.

    et al. Enhanced production and oligomerization of the 42-residue amyloid β-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272, 7977–7982 (1997).

  16. 16.

    et al. Increased Aβ42(43) from cell lines expressing presenilin 1 mutations. Ann. Neurol. 43, 256–258 (1998).

  17. 17.

    et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13, 45–53 (1994).

  18. 18.

    Amyloid-β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: predominance of Aβ42(43). Ann. Neurol. 40, 149– 156 (1996).

  19. 19.

    et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat. Med. 2, 1146–1150 (1996).

  20. 20.

    The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 55, 1023– 1025 (1996).

  21. 21.

    et al. Age, neurofibrillary changes, Aβ-amyloid and the onset of Alzheimer's disease. Neurosci. Lett. 210, 87– 90 (1996).

  22. 22.

    et al. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17, 7053– 7059 (1997).

  23. 23.

    et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523– 527 (1995).

  24. 24.

    et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99–102 (1996).

  25. 25.

    et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939–945 (1997).

  26. 26.

    et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97–100 ( 1998).

  27. 27.

    et al. A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport 7, 297– 301 (1995).

  28. 28.

    et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 4, 452–455 (1998).

  29. 29.

    et al. Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc. Natl Acad. Sci. USA 94, 7612– 7616 (1997).

  30. 30.

    et al. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077– 4081 (1996).

  31. 31.

    et al. Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J. Biol. Chem. 272, 16085 –16088 (1997).

  32. 32.

    et al. Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides. Nat. Med. 3, 1016– 1020 (1997).

  33. 33.

    et al. Intracellular Aβ1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J. Biol. Chem. 270, 14786– 14792 (1995).

  34. 34.

    Apolipoprotein E affects the rate of Alzheimer disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol. Exp. Neurol. 53, 429– 437 (1994).

  35. 35.

    et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921 –923 (1993).

  36. 36.

    Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. Am. J. Med. Genet. 81, 49– 57 (1998).

  37. 37.

    et al. Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia. Neuroreport 5, 2583–2585 (1994).

  38. 38.

    et al. APOE genotype and Alzheimer's disease. Lancet 342, 737–738 (1993).

  39. 39.

    et al. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Ann. Neurol. 38, 124 –127 (1995).

  40. 40.

    et al. APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. Neurosci. Lett. 169 , 179–180 (1994).

  41. 41.

    et al. E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Hum. Mutat. 10, 186– 195 (1997).

  42. 42.

    et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17, 263–264 (1997).

  43. 43.

    et al. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum. Mol. Genet. 7, 533–540 (1998).

  44. 44.

    et al. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum. Mol. Genet. 6, 2151– 2154 (1997).

  45. 45.

    et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 421, 105– 108 (1998).

  46. 46.

    et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat. Genet. 18, 69– 71 (1998).

  47. 47.

    , & Structure and novel exons of the human tau gene. Biochemistry 31, 10626– 10633 (1992).

  48. 48.

    , , , & Multiple isoforms of human microtubule-associated protein tau: sequence and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519– 526 (1989).

  49. 49.

    et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383 , 550–553 (1996).

  50. 50.

    et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815–826 (1998).

  51. 51.

    et al. Coding and 5' splice site mutations in tau associated with inherited dementia (FTDP-17). Nature 393, 702– 705 (1998).

  52. 52.

    et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737–7741 (1998).

  53. 53.

    et al. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of Tauopathies. Brain Pathol. 8, 387–402 (1998).

  54. 54.

    et al. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann. Neurol. 42, 564–572 (1997).

  55. 55.

    et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann. Neurol. 41, 706– 715 (1997).

  56. 56.

    et al. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their distribution and phosphorylation. Ann. Neurol. 43, 193–204 (1998).

Download references

Acknowledgements

Supported by the Mayo Foundation and by an NIA Program Project Grant and an NINDS Project Grant (M.H.).

Author information

Affiliations

  1. Neurogenetics and Transgenics Laboratories, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA

    • John Hardy
    • , Karen Duff
    • , Katrina Gwinn Hardy
    • , Jordi Perez-Tur
    •  & Mike Hutton

Authors

  1. Search for John Hardy in:

  2. Search for Karen Duff in:

  3. Search for Katrina Gwinn Hardy in:

  4. Search for Jordi Perez-Tur in:

  5. Search for Mike Hutton in:

Corresponding author

Correspondence to John Hardy.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/1565

Further reading